Assignee
GENETHON
FR·34 granted patents·52 pending applications·79 citations·filing 2003–2025
Top patents by PatentIndex Score
86 records- 0193US10166272B2Efficient systemic treatment of dystrophic muscle pathologiesGENETHON·Filed 2015·Granted Jan 1, 2019·16 cites·12 claims
- 0289US11421211B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2017·Granted Aug 23, 2022·4 cites·9 claims
- 0389US10752898B2Effective gene therapy tools for dystrophin exon 53 skippingGENETHON·Filed 2016·Granted Aug 25, 2020·34 cites·15 claims
- 0488US10786546B2Efficient systemic treatment of dystrophic muscle pathologiesGENETHON·Filed 2018·Granted Sep 29, 2020·3 cites·6 claims
- 0587US11339406B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2017·Granted May 24, 2022·3 cites·20 claims
- 0681US12351816B2CNS gene delivery using peripheral administration of AAV vectorsGENETHON·Filed 2023·Granted Jul 8, 2025·0 cites·8 claims
- 0780US2025333765A1Cns gene delivery using peripheral administration of aav vectorsGENETHON·Filed 2025·Application pending·0 cites
- 0879US10125352B2Method for producing enveloped virusesGENETHON·Filed 2014·Granted Nov 13, 2018·4 cites·7 claims
- 0977US12305187B2Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Granted May 20, 2025·0 cites·19 claims
- 1077US10465169B2Method for purifying enveloped viruses or viral vectorsGENETHON·Filed 2014·Granted Nov 5, 2019·4 cites·23 claims
- 1176US12037362B2Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropismGENETHON·Filed 2019·Granted Jul 16, 2024·1 cites·7 claims
- 1276US2025127930A1Hybrid regulatory elementsGENETHON·Filed 2024·Application pending·0 cites
- 1376US2024317814A1Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver TropismGENETHON·Filed 2024·Application pending·0 cites
- 1475US9862934B2Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virionsGENETHON·Filed 2015·Granted Jan 9, 2018·2 cites·8 claims
- 1575US2025270590A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2025·Application pending·0 cites
- 1673US10471132B2Treatment of hyperbilirubinemiaGENETHON·Filed 2015·Granted Nov 12, 2019·3 cites·19 claims
- 1772US11767538B2Widespread gene delivery to motor neurons using peripheral injection of AAV vectorsGENETHON·Filed 2019·Granted Sep 26, 2023·0 cites·13 claims
- 1871US11371061B2Compositions and methods for improving viral vector efficiencyGENETHON·Filed 2016·Granted Jun 28, 2022·2 cites·11 claims
- 1970US12023366B2Efficient systemic treatment of dystrophic muscle pathologiesGENETHON·Filed 2020·Granted Jul 2, 2024·0 cites·9 claims
- 2070US2024043867A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Application pending·0 cites
- 2169US11236307B2Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virionsGENETHON·Filed 2019·Granted Feb 1, 2022·0 cites·21 claims
- 2269US9981049B2Selective gene therapy expression systemGENETHON·Filed 2014·Granted May 29, 2018·1 cites·10 claims
- 2368US12582723B2Polynucleotides encoding a human FKRP proteinGENETHON·Filed 2023·Granted Mar 24, 2026·0 cites·9 claims
- 2467US2023414724A1Treatment of hyperbilirubinemiaGENETHON·Filed 2023·Application pending·0 cites
- 2567US2019153474A1Cns gene delivery using peripheral administration of aav vectorsGENETHON·Filed 2018·Application pending·0 cites
- 2666US9526742B2Use of epigenome-modifying compounds for the treatment of genetic muscular diseases linked to a protein-conformational disorderGENETHON·Filed 2013·Granted Dec 27, 2016·1 cites·2 claims
- 2766US2022235371A1Scalable lentiviral vector production system compatible with industrial pharmaceutical applicationsGENETHON·Filed 2021·Application pending·0 cites
- 2865US2022389399A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2022·Application pending·0 cites
- 2964US11819478B2Selective gene therapy expression systemGENETHON·Filed 2018·Granted Nov 21, 2023·0 cites·16 claims
- 3064US2026053923A1Immunotherapy of Skeletal Myopathies Using ANTI-FAP CAR-T CellsGENETHON·Filed 2023·Application pending·0 cites
- 3163US2023190965A1Treatment of glycogen storage disease iiiGENETHON·Filed 2022·Application pending·0 cites
- 3262US12171843B2Hybrid regulatory elementsGENETHON·Filed 2019·Granted Dec 24, 2024·0 cites·13 claims
- 3360US9933438B2Method for diagnosing muscular dystrophyGENETHON·Filed 2013·Granted Apr 3, 2018·1 cites·9 claims
- 3460US2019211360A1Scalable lentiviral vector production system compatible with industrial pharmaceutical applicationsGENETHON·Filed 2019·Application pending·0 cites
- 3560US2021040503A1Acid-alpha glucosidase variants and uses thereofGENETHON·Filed 2020·Application pending·0 cites
- 3660US2022228167A1Peptide-Modified Hybrid Recombinant Adeno-Associated Virus Serotype Between AAV9 and AAVrh74 with Reduced Liver Tropism and Increased Muscle TransductionGENETHON·Filed 2019·Application pending·0 cites
- 3760US2024350670A1Hybrid promoters for gene expression in muscles and in the cnsGENETHON·Filed 2022·Application pending·0 cites
- 3859US2023117384A1Compositions and methods for improving viral vector efficiencyGENETHON·Filed 2022·Application pending·0 cites
- 3958US10428315B2Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virionsGENETHON·Filed 2017·Granted Oct 1, 2019·0 cites·27 claims
- 4057US11993781B2Stable pseudotyped lentiviral particles and uses thereofGENETHON·Filed 2017·Granted May 28, 2024·0 cites·5 claims
- 4157US2024209030A1Peptide-Modified AAV CapsidGENETHON·Filed 2021·Application pending·0 cites
- 4256US11541131B2Treatment of glycogen storage disease IIIGENETHON·Filed 2018·Granted Jan 3, 2023·0 cites·21 claims
- 4356US10767192B2Baculovirus system for the expression of a gene therapy vectorGENETHON·Filed 2018·Granted Sep 8, 2020·0 cites·21 claims
- 4456US2023242905A1Method for Engineering Novel Hybrid AAV Capsids Through Hyper Variable Regions SwappingGENETHON·Filed 2021·Application pending·0 cites
- 4556US2023250450A1NRF2 Activator for Use in Treating Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
- 4656US2023265427A1Treatment of Genetic Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
- 4756US2023220391A1CILP-1 Inhibitors for Use in the Treatment of Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
- 4855US2023203534A1Vectors encoding a glucose-6-phosphatase (g6pase-a) for gene therapyGENETHON·Filed 2021·Application pending·0 cites
- 4954US2009220468A1Specific CD4+CD25+ Regulatory T Cells for Haematopoietic Cell Transplantation and Immune ToleranceGENETHON·Filed 2007·Application pending·0 cites
- 5053US2023277540A1Treatment of Dilated CardiomyopathiesGENETHON·Filed 2021·Application pending·0 cites
Showing the top 50 of 86 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when GENETHON files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →